STOCK TITAN

AstraZeneca PLC - $AZN STOCK NEWS

Welcome to our dedicated page for AstraZeneca PLC news (Ticker: $AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca PLC stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AstraZeneca PLC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AstraZeneca PLC's position in the market.

Rhea-AI Summary
AbelZeta Pharma, Inc. announced the acceptance of an abstract related to the clinical study of C-CAR031, a CAR-T therapy for hepatocellular carcinoma, at the 2024 ASCO Annual Meeting. The therapy is developed in collaboration with AstraZeneca and will be presented in June 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
none
-
News
Rhea-AI Summary
AstraZeneca reports very strong Q1 2024 financial results with a 19% increase in total revenue, driven by growth in product sales and alliance revenue. Core EPS grew by 13% to $2.06. The company reaffirmed its guidance for FY 2024, expecting double-digit growth in revenue and EPS. Key milestones include positive trial results for Imfinzi and Tagrisso in lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
-
Rhea-AI Summary
Asher Biotherapeutics closes $55 million Series C financing led by RA Capital Management to advance lead program AB248 into Phase 1b Clinical Trials with support from AstraZeneca and Bristol Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
Rhea-AI Summary
AstraZeneca's IMFINZI in combination with chemotherapy doubled the overall survival rate at three years for patients with advanced biliary tract cancer in the TOPAZ-1 Phase III trial. The results showed a 26% reduction in the risk of death compared to chemotherapy alone, with a median OS of 12.9 months for the combination therapy. The trial met the primary endpoint of OS in October 2021, showing a 20% reduction in the risk of death. IMFINZI plus chemotherapy continued to be well-tolerated with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
-
Rhea-AI Summary
AstraZeneca's FASENRA (benralizumab) receives FDA approval for pediatric patients aged 6 to 11 with severe eosinophilic asthma, expanding treatment options. The approval is based on TATE trial data and prior trials, with a recommended dose of 30 mg for patients 6 years and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's ENHERTU receives U.S. FDA approval for the treatment of HER2 positive solid tumors after showing clinically meaningful responses. The drug is now approved for five indications, with the latest in metastatic cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU gains accelerated approval in the US for HER2-positive solid tumors, marking a significant milestone in targeted cancer treatment. The approval is based on positive response rates and duration of response in Phase II trials, leading to inclusion in NCCN Guidelines®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
Rhea-AI Summary
AstraZeneca's IMFINZI shows survival benefit in Phase III trial for -stage small cell lung cancer, marking a breakthrough in treatment. Positive results in OS and PFS with no new safety signals identified. IMFINZI continues to lead in lung cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
-
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of advanced nonsquamous non-small cell lung cancer and HR positive, HER2 negative breast cancer. The BLA is based on positive results from the TROPION-Breast01 phase 3 trial, with a PDUFA date set for January 29, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
Rhea-AI Summary
VOYDEYA (danicopan) has been approved in the US as an add-on therapy for extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. The approval was based on positive results from the pivotal ALPHA Phase III trial, showing efficacy in addressing EVH. VOYDEYA met primary and secondary endpoints, was well-tolerated, and received Breakthrough Therapy designation and PRIME status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
AstraZeneca PLC

Nasdaq:AZN

AZN Rankings

AZN Stock Data

243.51B
1.54B
0.01%
16.8%
0.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.